| Literature DB >> 29150475 |
Thomas Agoritsas1,2,3, Arnaud Merglen4, Anja Fog Heen5, Annette Kristiansen5, Ignacio Neumann3,6, Juan P Brito7, Romina Brignardello-Petersen3,8, Paul E Alexander3, David M Rind9, Per O Vandvik5,10, Gordon H Guyatt3.
Abstract
INTRODUCTION: UpToDate is widely used by clinicians worldwide and includes more than 9400 recommendations that apply the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. GRADE guidance warns against strong recommendations when certainty of the evidence is low or very low (discordant recommendations) but has identified five paradigmatic situations in which discordant recommendations may be justified.Entities:
Keywords: clinical decision making; clinical practice guidelines; evidence-based medicine; quality of the evidence; strength of recommendations
Mesh:
Year: 2017 PMID: 29150475 PMCID: PMC5701989 DOI: 10.1136/bmjopen-2017-018593
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Paradigmatic situations in which a strong recommendation may be warranted despite low or very low certainty in effect estimates (appropriate strength, consistent with Grading of Recommendations Assessment, Development and Evaluation (GRADE))
| Situation | Certainty in estimates | Balance of benefits and harms | Values and preferences | Resource considerations | Recommendation | Example | |
| Benefits | Harms | ||||||
| 1. Life-threatening (or catastrophical) situation | Low or very low | Immaterial | Intervention may reduce mortality in a life-threatening situation; adverse events not prohibitive | A very high value is placed on an uncertain but potentially life-preserving benefit | Small incremental cost (or resource use) relative to the benefits justify the intervention | Strong recommendation in favour of the intervention | Indirect evidence from seasonal influenza suggests that patients with avian influenza may benefit from the use of oseltamivir (low certainty in effect estimates). Given the high mortality of the disease and the absence of effective alternatives, the WHO made a strong recommendation in favour of the use of oseltamivir rather than no treatment in patients with avian influenza. |
| 2. Uncertain benefit, certain harm | Low or very low | High or moderate | Possible but uncertain benefit; substantial established harm | A much higher value is placed on the adverse events in which we are confident than in the benefit, which is uncertain | High incremental cost (or resource use) relative to the benefits may not justify the intervention | Strong recommendation against the intervention | In patients with idiopathic pulmonary fibrosis, treatment with azathioprine plus prednisone offers a possible but uncertain benefit in comparison with no treatment. The intervention, however, is associated with a substantial established harm. An international guideline made a recommendation against the combination of corticosteroids plus azathioprine in patients with idiopathic pulmonary fibrosis. |
| 3. Potential equivalence, one option clearly less risky or costly | Low or very low | High or moderate | Magnitude of benefit apparently similar—though uncertain—for alternatives; we are confident less harm or cost for one of the competing alternatives | A high value is placed on the reduction in harm | High incremental cost (or resource use) relative to the benefits may not justify one of the alternatives | Strong recommendation for less harmful/less expensive | Low-quality evidence suggests that initial |
| 4. High certainty in similar benefits, one option potentially more risky or costly | High or moderate | Low or very low | Established that magnitude of benefit is similar for alternative management strategies; best (though uncertain) estimate is that one alternative has appreciably greater harm | A high value is placed on avoiding the potential increase in harm | High incremental cost | Strong recommendation against the intervention with possible greater harm | In women requiring anticoagulation and planning conception or in pregnancy, high certainty estimates suggest similar effects of different anticoagulants. However, indirect evidence (low certainty in effect estimates) suggests potential harm to the unborn infant with oral direct thrombin (eg, dabigatran) and factor Xa inhibitors (eg, rivaroxaban, apixaban). The AT9 guidelines recommended against the use of such anticoagulants in women planning conception or in pregnancy. |
| 5. Potential catastrophic harm | Immaterial | Low or very low | Potential important harm of the intervention, magnitude of benefit is variable | A high value is placed on avoiding potential increase in harm | High incremental cost | Strong recommendation against the intervention | In males with androgen deficiency, testosterone supplementation likely improves quality of life. Low-certainty evidence suggests that testosterone increases cancer spread in patients with prostate cancer. The US Endocrine Society made a recommendation against testosterone supplementation in patients with prostate cancer. |
Reproduced and adapted from Neumann et al.13
MALT, mucosa-associated lymphoid tissue.
Reasons for issuing strong recommendation based on low certainty in effect estimates inconsistent with Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance
| Situation | Example |
| Best practice recommendation | “For patients with congenital adrenal hyperplasia, we recommend monitoring patients for signs of glucocorticoid excess, as well as for signs of inadequate androgen suppression.” This statement should not have been GRADEd as sensible alternatives do not exist. |
| The strong recommendation was warranted because the certainty of the evidence was actually moderate rather then low | “We recommend intensive lifestyle modification to the entire family and to the patient, and as the prerequisite for all overweight and obesity treatments for children and adolescents.” The authors classified this as low quality evidence; our judgement is that the correct classification is moderate quality. |
| Lack of compelling explanation | “If a patient is unable or unwilling to undergo surgery, we recommend medical treatment with mineralocorticoids’. Lack of evidence of mineralocorticoids being superior to other medical treatment (eg, antihypertensive medications).” |
Elements adapted from Brito et al.11
Distribution of the strength of the recommendations in UpToDate according to the certainty in evidence
| Weak | Strong | All | |
| n (%) | n (%) | n (%) | |
| Low certainty | 4335 (66.7) | 366 (12.4) | 4701 (49.7) |
| Moderate certainty | 2019 (31.1) | 1740 (59.0) | 3759 (39.8) |
| High certainty | 147 (2.3) | 844 (28.6) | 991 (10.5) |
| Total | 6501 (68.8% of all rec) | 2950 (31.2% of all rec) | 9451 (100) |
Characteristics of all 349 discordant recommendations in UpToDate and proportion of appropriate discordant recommendations
| n (%) | Per cent of appropriate discordant (P value) | |
| Clinical Specialties | (P=0.160)* | |
| Primary Care and General internal Medicine | 15(4.3) | 53.3 |
| Emergency Medicine | 16(4.6) | 81.3 |
| Critical Care | 5(1.4) | 80.0 |
| Internal Medicine specialties | 158(45.3) | 57.6 |
| Oncology (including haemato-oncology) | 43(12.3) | 55.8 |
| Paediatrics | 73(20.9) | 47.9 |
| Obstetrics, Gynaecology and Women Health | 19(5.4) | 73.7 |
| General Surgery | 13(3.7) | 69.2 |
| Anaesthesiology | 3(0.9) | 100.0 |
| Psychiatry | 4(1.1) | 75.0 |
| Intervention type | (P=0.010) | |
| Drug intervention | 197(56.4) | 61.4 |
| Surgical interventions | 69(19.8) | 59.4 |
| Medical device | 24(6.9) | 62.5 |
| Behavioural or multidisciplinary intervention | 35(10.0) | 57.1 |
| Diagnostic test, screening programmes | 24(6.9) | 29.2 |
| Clarity of the comparator | (P<0.001) | |
| Comparator not at all clear—uncertain | 46(13.2) | 37.0 |
| Comparator not clearly and explicitly stated or obvious but relatively easy to infer | 120(34.4) | 48.3 |
| Comparator not clearly and explicitly stated but obvious | 110(31.5) | 68.2 |
| Comparator clearly and explicitly stated | 73(20.9) | 74.0 |
| Type of comparator | (P=0.083) | |
| Too unclear | 25(7.2) | 44.0 |
| No intervention (or placebo) | 126(36.1) | 54.0 |
| Other intervention(s) (standard of care or alternative(s)) | 198(56.7) | 63.1 |
| Direction of the recommendation | (P<0.001) | |
| For the intervention (ie, against the comparator) | 274(78.5) | 51.1 |
| Against the intervention (ie, for the comparator) | 75(21.5) | 85.3 |
| Mortality | (P<0.001) | |
| No statement about mortality | 189(54.2) | 47.1 |
| Implicit statement about mortality | 47(13.5) | 68.1 |
| Explicit statement about mortality | 113(32.4) | 73.5 |
| Balance of benefits and harms | (P<0.001) | |
| No statement about the balance of outcomes | 100(28.7) | 28.0 |
| Implicit statement about the balance of outcomes | 157(45.0) | 66.9 |
| Explicit statement about the balance of outcomes | 92(26.4) | 77.2 |
| Relative importance of outcomes—values and preferences | (P<0.001) | |
| No statement about the relative importance of outcomes | 168(48.1) | 42.9 |
| Implicit statement about the relative importance of outcomes | 171(49.0) | 73.1 |
| Explicit statement about the relative importance of outcomes | 10(2.9) | 70.0 |
| Cost of resources | (P=0.023) | |
| No statement about cost or resources | 334(95.7) | 57.2 |
| Cost or resources clearly and explicitly stated | 15(4.3) | 86.7 |
| Supporting SR | (P=0.175) | |
| No SR is cited | 300(86.0) | 56.3 |
| SR of observational studies | 22(6.3) | 63.6 |
| SR of both RCT and observational studies | 13(3.7) | 76.9 |
| SR of RCT | 14(4.0) | 78.6 |
| Design of primary studies | (P=0.002) | |
| No reference cited | 45(12.9) | 35.6 |
| Other type (eg, narrative review, book chapter) | 48(13.8) | 54.2 |
| Observational studies | 203(58.2) | 61.1 |
| RCT | 53(15.2) | 71.7 |
| Total | 349(100) | 58.5 |
*The null hypothesis for the p value is that the proportions do not differ across categories.
RCT, randomised controlled trials; SR, systematic review.
Summary judgements on the appropriateness of 349 discordant strong recommendation based on low certainty in effect in UpToDate
| n(%) | |
| Appropriate discordant recommendations (consistent with GRADE) | |
| 1. Life-threatening (or catastrophical) situation | 70(20.1) |
| 2. Uncertain benefit, certain harm | 28(8.0) |
| 3. Potential similar benefits, one clearly less risky (or costly) | 56(16.0) |
| 4. Established similar benefits, one potentially more risky (or costly) | 18(5.2) |
| 5. Potential catastrophic harm | 32(9.2) |
| Total | 204(58.5) |
| Inappropriate discordant recommendations (inconsistent with GRADE) | |
| 6. Good practice statement | 47(13.5) |
| 7. Misclassification of certainty (judged moderate or high) | 38(10.9) |
| 8. Lack of explanation, should have been weak recommendation (GRADE 2C) | 60(17.2) |
| Total | 145(41.5) |
GRADE, Grading of Recommendations Assessment, Development and Evaluation.